These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33837065)

  • 21. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.
    Kato D; Yaguchi T; Iwata T; Katoh Y; Morii K; Tsubota K; Takise Y; Tamiya M; Kamada H; Akiba H; Tsumoto K; Serada S; Naka T; Nishimura R; Nakagawa T; Kawakami Y
    Elife; 2020 Mar; 9():. PubMed ID: 32228854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
    Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z
    Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.
    Deng C; Zhao J; Zhou S; Dong J; Cao J; Gao J; Bai Y; Deng H
    Mol Ther; 2020 Jan; 28(1):75-88. PubMed ID: 31672285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
    Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
    Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
    Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
    Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
    Sullivan PM; Reed SJ; Kalia V; Sarkar S
    Front Immunol; 2021; 12():706150. PubMed ID: 34867942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
    Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
    Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.
    Yeku OO; Purdon TJ; Koneru M; Spriggs D; Brentjens RJ
    Sci Rep; 2017 Sep; 7(1):10541. PubMed ID: 28874817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity.
    Sánchez-Paulete AR; Mateus-Tique J; Mollaoglu G; Nielsen SR; Marks A; Lakshmi A; Khan JA; Wilk CM; Pia L; Baccarini A; Merad M; Brown BD
    Cancer Immunol Res; 2022 Nov; 10(11):1354-1369. PubMed ID: 36095236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
    Weimin S; Abula A; Qianghong D; Wenguang W
    Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
    [No Abstract]   [Full Text] [Related]  

  • 34. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function.
    Johnson LR; Lee DY; Eacret JS; Ye D; June CH; Minn AJ
    Cell; 2021 Sep; 184(19):4981-4995.e14. PubMed ID: 34464586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.
    Li X; Berahovich R; Zhou H; Liu X; Li F; Xu S; Wei Y; Ouaret D; Bodmer W; Wu L; Golubovskaya V
    Front Biosci (Landmark Ed); 2020 Jun; 25(9):1765-1786. PubMed ID: 32472757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
    Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.